The Impact of Different Antidiabetic Drugs on Fracture Risk in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials With a Focus on SGLT2 Inhibitors

Authors

Bushra Admani
Fizza Z. Raza
Fatima Siddiqui
Muhammad T. Ashraf
Muhammad K. Khan
Ifra Habib
Ayesha Usman
Bareeha Mansoor
Zaira Nadeem
Rana J. Ghaffer
Muhammad Riyyan
Sawaira Sajid
Muhammad H. A. Chania
Mahnoor Saleem
Saad Javaid
Nikhil Duseja
Hussam Al Hennawi, Thomas Jefferson UniversityFollow
Sunita Lakhani, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

8-20-2025

Comments

This article is the author’s final published version in American Journal of Medicine Open, Volume 14, 2025, Article number 100115.

The published version is available at https://doi.org/10.1016/j.ajmo.2025.100115. Copyright © 2025 The Authors.

Abstract

SGLT2 inhibitors are a new class of antidiabetic drugs that have shown cardiovascular benefits in patients with type 2 diabetes mellitus (T2DM) and cardiovascular disease. However, their effects on fracture risk are unclear and may depend on the type and duration of treatment. This meta-analysis compares the fracture risk of different antidiabetic drugs, including SGLT2 inhibitors, based on data from randomized controlled trials (RCTs). We searched 4 databases for RCTs that reported fracture events in patients with T2DM who received different antidiabetic drugs. We included 117 RCTs that compared 9 types of antidiabetic drugs: SGLT2 inhibitors, DPP-4 inhibitors, α-glucosidase inhibitors, thiazolidinediones, insulin, GLP-1 receptor agonists, meglitinides, biguanides, and sulfonylureas. We used a statistical method called Frequentist meta-analysis to combine data from different studies and compare different treatments. The results showed that SGLT2 inhibitors were the only drug that significantly reduced the fracture risk compared to placebo and other drugs (OR 0.85; 95% CI, 0.74-0.98). The other antidiabetic drugs did not show any significant difference from placebo or from each other. The mechanisms behind the effects of SGLT2 inhibitors on bone health are not well understood and may involve changes in calcium, phosphate, sodium, and arginine vasopressin levels in the body. SGLT2 inhibitors demonstrated a favorable skeletal safety profile among antidiabetic drugs. More long-term studies focused on fracture as a primary outcome are needed to fully understand how SGLT2 inhibitors affect bone health and fracture risk in patients with T2DM.

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License

Recommended Citation

Admani, Bushra; Raza, Fizza Z.; Siddiqui, Fatima; Ashraf, Muhammad T.; Khan, Muhammad K.; Habib, Ifra; Usman, Ayesha; Mansoor, Bareeha; Nadeem, Zaira; Ghaffer, Rana J.; Riyyan, Muhammad; Sajid, Sawaira; Chania, Muhammad H. A.; Saleem, Mahnoor; Javaid, Saad; Duseja, Nikhil; Al Hennawi, Hussam; and Lakhani, Sunita, "The Impact of Different Antidiabetic Drugs on Fracture Risk in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials With a Focus on SGLT2 Inhibitors" (2025). Abington Jefferson Health Papers. Paper 136.
https://jdc.jefferson.edu/abingtonfp/136

Language

English